Certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-03. Anything still debated is marked as such rather than presented as settled.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C for solid; 2-8 °C for short-term solution use | Avoid repeated freeze-thaw cycles |
| Preferred solvent | Water or aqueous buffer near neutral pH | Nonpolar solvents give poor dissolution |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Copper quantified separately by ICP-MS |
| Principal degradation routes | Backbone hydrolysis, histidine oxidation, photolysis | Alkaline pH accelerates hydrolysis |
| Counterion form | Acetate salt is common | Counterion contributes to measured mass |
Analytical verification typically combines reversed-phase high-performance liquid chromatography with ultraviolet-visible detection. The copper complex absorbs visible light near 600–630 nm, giving a characteristic blue signal. Mass spectrometry confirms molecular mass and can detect free peptide or mismatched copper stoichiometry. Copper content is often measured independently by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. Purity, counterion identity, and residual solvents are additional quality-control parameters that methods may address.
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
== Bibliography == Schiffman MA (2010). Autologous Fat Transfer: Art, Science, and Clinical Practice. Berlin, Heidelberg: Springer. ISBN 978-3-642-00472-8. Mary White Stewart MD (2012). Silicone Spills: Breast Implants on Trial. Santa Barbara, CA: Praeger. ISBN 978-0-275-96359-0.
Increased body temperature >38 °C (>100.4 °F) Confused or altered consciousness Excessive sweating Severely rigid muscles Autonomic imbalance The first symptoms of neuroleptic malignant syndrome are usually muscle cramps and tremors, fever, symptoms of autonomic nervous system instability such as unstable blood pressure, and sudden changes in mental status (agitation, delirium, or coma). Other possible symptoms include sweating, trouble swallowing, incontinence, and mutism. Once symptoms appear, they may progress rapidly and reach peak intensity in as little as three days. These symptoms can last anywhere from eight hours to forty days, with the median duration of symptoms, with treatment, being nine days. The median onset of symptoms is four days after initiating the offending medication, but in some cases symptoms may begin up to 30 days later. Symptoms are sometimes misinterpreted by doctors as symptoms of mental illness which can result in delayed treatment. Symptoms may also be mistaken for similarly presenting conditions such as malignant hyperthermia, serotonin syndrome, and substance intoxication from illicit drugs such as cocaine, methamphetamine, or MDMA. Neuroleptic malignant syndrome (NMS) usually presents with a "lead pipe rigidity" in which the muscles are stiffened and resistance is observed throughout the range of motion on testing. Severe cases may present as catatonia in which the person is not responsive to stimuli. The deep tendon reflexes in NMS are usually preserved whereas serotonin syndrome presents with myoclonus or hyperactive muscle reflexes.
In 1912, the first deposit of distinct, single-crystal turquoise was discovered at Lynch Station in Campbell County, Virginia. The crystals, forming a druse over the mother rock, are very small; 1 mm (0.04 in) is considered large. Until the 1980s Virginia was widely thought to be the only source of distinct crystals; there are now at least 27 other localities. In an attempt to recoup profits and meet demand, some American turquoise is treated or enhanced to a certain degree. These treatments include innocuous waxing and more controversial procedures, such as dyeing and impregnation (see Treatments). There are some American mines which produce materials of high enough quality that no treatment or alterations are required. Any such treatments which have been performed should be disclosed to the buyer on sale of the material.
MRI is the investigative tool of choice for neurological cancers over CT, as it offers better visualization of the posterior cranial fossa, containing the brainstem and the cerebellum. The contrast provided between grey and white matter makes MRI the best choice for many conditions of the central nervous system, including demyelinating diseases, dementia, cerebrovascular disease, infectious diseases, Alzheimer's disease and epilepsy. Since multiple images are taken milliseconds apart, it can show how the brain responds to different stimuli, enabling researchers to study both functional and structural brain abnormalities in psychological disorders. MRI also is used in guided stereotactic surgery and radiosurgery for treatment of intracranial tumors, arteriovenous malformations, and other surgically treatable conditions using a device known as the N-localizer. New tools that implement artificial intelligence in healthcare have demonstrated higher image quality and morphometric analysis in neuroimaging with the application of a denoising system. More broadly, deep learning has been applied to accelerate MRI acquisition itself by reconstructing diagnostic-quality images from undersampled k-space data. The fastMRI project, a collaboration between Meta AI Research (FAIR) and NYU Langone Health launched in 2018, released the largest open-source dataset of raw MRI measurements and demonstrated that AI-based reconstruction can achieve up to 4× acceleration of knee and brain scans with no loss of diagnostic accuracy—a result confirmed in a clinical interchangeability study.
Sources: en.wikipedia.org
Adiponectin (also referred to as GBP-28, apM1, AdipoQ and Acrp30) is a protein hormone and adipokine, which is involved in regulating glucose levels and fatty acid breakdown. In humans, it is encoded by the ADIPOQ gene and is produced primarily in adipose tissue, but also in muscle and even in the brain.
Flutamide, sold under the brand name Eulexin among others, is a nonsteroidal antiandrogen (NSAA) which is used primarily to treat prostate cancer. It is also used in the treatment of androgen-dependent conditions like acne, excessive hair growth, and high androgen levels in women. It is taken by mouth, usually three times per day. Side effects in men include breast tenderness and enlargement, feminization, sexual dysfunction, and hot flashes. Conversely, the medication has fewer side effects and is better-tolerated in women with the most common side effect being dry skin. Diarrhea and elevated liver enzymes can occur in both sexes. Rarely, flutamide can cause liver damage, lung disease, sensitivity to light, elevated methemoglobin, elevated sulfhemoglobin, and deficient neutrophils. Numerous cases of liver failure and death have been reported, which has limited the use of flutamide. Flutamide acts as a selective antagonist of the androgen receptor (AR), competing with androgens like testosterone and dihydrotestosterone (DHT) for binding to ARs in tissues like the prostate gland. By doing so, it prevents their effects and stops them from stimulating prostate cancer cells to grow. Flutamide is a prodrug to a more active form. Flutamide and its active form stay in the body for a relatively short time, which makes it necessary to take flutamide multiple times per day. Flutamide was first described in 1967 and was first introduced for medical use in 1983. It became available in the United States in 1989.
Gamma irradiation is widely used due to its high penetration depth and dose uniformity, allowing for large-scale applications with high throughput. Additionally, gamma irradiation is significantly less expensive than using an X-ray source. In most designs, the radioisotope, contained in stainless steel pencils, is stored in a water-filled storage pool which absorbs the radiation energy when not in use. For treatment, the source is lifted out of the storage tank, and product contained in totes is passed around the pencils to achieve required processing. Treatment costs vary as a function of dose and facility usage. A pallet or tote is typically exposed for several minutes to hours depending on dose. Low-dose applications such as disinfestation of fruit range between US$0.01/lb and US$0.08/lb while higher-dose applications can cost as much as US$0.20/lb.
[Ca2+]max = Ksp/Ka2 × [H+]/[HCO−3] The solubility product for CaCO3 (Ksp) and the dissociation constants for the dissolved inorganic carbon species (including Ka2) are all substantially affected by temperature and salinity, with the overall effect that [Ca2+]max increases from freshwater to saltwater, and decreases with rising temperature, pH, or added bicarbonate level, as illustrated in the accompanying graphs. The trends are illustrative for pool management, but whether scaling occurs also depends on other factors including interactions with Mg2+, [B(OH)4]− and other ions in the pool, as well as supersaturation effects. Scaling is commonly observed in electrolytic chlorine generators, where there is a high pH near the cathode surface and scale deposition further increases temperature. This is one reason that some pool operators prefer borate over bicarbonate as the primary pH buffer, and avoid the use of pool chemicals containing calcium.
== Medical diagnosis and treatment == Medicine is mainly focused on the art of diagnosis and treatment with medication. The diagnostic process involves gathering data, generating one or more diagnostic hypotheses, and iteratively testing these potential diagnoses against dynamic disease profiles to determine the best course of action for the patient.
Sources: en.wikipedia.org
Reaction (1) is only possible if energetically allowed, i.e. if the proton affinity of R is higher than the proton affinity of H2O (691 kJ/mol). As most components of ambient air possess a lower proton affinity than H2O (e.g. N2, O2, Ar, CO2, etc.) the H3O+ ions only react with VOC trace components and the air itself acts as a buffer gas. Moreover, due to the low concentrations of trace components one can assume that the total number of H3O+ ions remains nearly unchanged, which leads to the equation
== External links == Clinical trial number NCT01340872 for "Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1) (AEGIS-1)" at ClinicalTrials.gov Clinical trial number NCT01352221 for "Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2) (AEGIS-2)" at ClinicalTrials.gov Clinical trial number NCT02968368 for "Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease (AEGIS-CKD)" at ClinicalTrials.gov Clinical trial number NCT05126901 for "Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years (FORTIS)" at ClinicalTrials.gov
Nihonium is a synthetic chemical element; it has symbol Nh and atomic number 113. It is extremely radioactive: its most stable known isotope, nihonium-286, has a half-life of about 10 seconds. In the periodic table, nihonium is a transactinide element in the p-block. It is a member of period 7 and group 13. Nihonium was first reported to have been created in experiments carried out between 14 July and 10 August 2003, by a Russian–American collaboration at the Joint Institute for Nuclear Research (JINR) in Dubna, Russia, working in collaboration with the Lawrence Livermore National Laboratory in Livermore, California, and on 23 July 2004, by a team of Japanese scientists at Riken in Wakō, Japan. The confirmation of their claims in the ensuing years involved independent teams of scientists working in the United States, Germany, Sweden, and China, as well as the original claimants in Russia and Japan. In 2015, the IUPAC/IUPAP Joint Working Party recognised the element and assigned the priority of the discovery and naming rights for the element to Riken. The Riken team suggested the name nihonium in 2016, which was approved in the same year. The name comes from the common Japanese name for Japan (日本, Nihon). Very little is known about nihonium, as it has been made only in very small amounts that decay within seconds. The anomalously long lives of some superheavy nuclides, including some nihonium isotopes, are explained by the island of stability theory.
== Polymyositis as a distinct diagnosis == The discovery of several myositis-specific autoantibodies during the past decades has enabled the description of other discrete subsets of diagnosis, specifically the discovery of Antisynthetase syndrome in reducing the number of diagnoses of polymyositis.
Over the first three-quarters of the 19th century, many experimenters worked with various combinations of platinum or iridium wires, carbon rods, and evacuated or semi-evacuated enclosures. Many of these devices were demonstrated and some were patented. In 1835, James Bowman Lindsay demonstrated a constant electric light at a public meeting in Dundee, Scotland. He stated that he could "read a book at a distance of one and a half feet". However he did not develop the electric light any further. In 1838, Belgian lithographer Marcellin Jobard invented an incandescent light bulb with a vacuum atmosphere using a carbon filament. In 1840, British scientist Warren De la Rue enclosed a coiled platinum filament in a vacuum tube and passed an electric current through it. The design was based on the concept that the high melting point of platinum would allow it to operate at high temperatures and that the evacuated chamber would contain fewer gas molecules to react with the platinum, improving its longevity. Although a workable design, the cost of the platinum made it impractical for commercial use. In 1841, Frederick de Moleyns of England was granted the first patent for an incandescent lamp, with a design using platinum wires contained within a vacuum bulb. He also used carbon. In 1845, American John W. Starr patented an incandescent light bulb using carbon filaments. His invention was never produced commercially. In 1851, Jean Eugène Robert-Houdin publicly demonstrated incandescent light bulbs on his estate in Blois, France.
Sources: en.wikipedia.org
The solid is typically held cold and dry, and solutions are kept for shorter periods because hydrolysis proceeds in water. Repeated freeze-thaw cycles are usually avoided, since they can degrade both the peptide and the complex. Container material and headspace also affect how long a sample remains unchanged.
Copper is quantified by an elemental technique such as inductively coupled plasma mass spectrometry, not by peptide chromatography. The chromatographic result describes the peptide chain, while the elemental result describes the metal. Reporting both is what makes the stoichiometry checkable.
It normally lists the analytical methods used, the measured purity, the appearance, and any residuals or counterions detected. It is a statement about a specific batch rather than a general property of the material. Independent testing is still needed when results must be traceable to a reference standard.
Identification usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. The copper content can be measured separately by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. The combination helps distinguish the intact complex from free peptide or free copper.